You are hereHome > Investor Relations
2:15 PM ET
|Stifel 2015 Healthcare Conference Investor Presentation
Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance
OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.
Currently, we have two candidates in clinical development across multiple oncology therapeutic areas and an additional candidate in pre-clinical development:
Phase 3 in prostate and lung cancers
OncoGenex's lead compound, custirsen, is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance.
Phase 2 in bladder, lung, pancreatic and prostate cancers
Apatorsen (OGX-427) is an investigational drug designed to inhibit the production of heat shock protein (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer cell growth and tumor metastasis. Learn More.
Webcasts & Presentations
Nov 18, 2015
2:15 PM ET
|Stifel 2015 Healthcare Conference Investor Presentation||Listen to webcast||View Presentation 1.9 MB|
Nov 12, 2015
4:30 PM ET
|OncoGenex Third Quarter 2015 Conference Call||Listen to webcast|
Aug 13, 2015
4:30 PM ET
|OncoGenex Second Quarter 2015 Conference Call||Listen to webcast|
You are now exiting the OncoGenex Web site and entering a third party Web site.
OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2015 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.